India’s regulator has allowed Serum Institute to conduct trials of vaccine against Kovid-19 on children aged 7-11 years. Serum is already using a vaccine on children 12-17 years old. Serum is testing a vaccine from the American company Novavax for children aged 7-11 years. Serum is making this vaccine in India under the name Kovavax. Schools that have been closed for about one and a half years in India are now slowly being opened and the need to vaccinate children is also being emphasized. Regarding this trial of vaccine for children, a committee of experts from the Central Drugs Standard Control Organization said, “After detailed discussion, the committee decided to allow children in the age group of 7 to 11 years to be admitted for the trial as per the protocol. Recommends “Children Awaiting Vaccination Serum is already testing Kovovax on 12-17 year olds and has also presented safety data for the initial 100 participants. This vaccine has not yet been approved by the health agencies of the Government of India. About 87 crore adults of the country’s 1.4 billion population have been given at least the first dose.
A few days ago, Serum Institute owner Adar Poonawalla said that he was expecting Kovovax to be approved for people under 18 by January or February next year. So far only Zydus Cadila’s DNA Kovid-19 vaccine has been given emergency approval to be given to children above 12 years in India. Improvements in India Novovax last year announced a license agreement with Serum to produce Kovovax in middle- and low-income countries. Serum has selected 10 Indian institutions for the trial of Kovovax. A total of 920 participants will participate in this trial. Apart from this, Serum is also making Russian vaccine Sputnik Lite and Poonawalla has said that his company will start commercial production after getting its license in India. Meanwhile, in India, the number of daily Kovid-19 infection cases reported on 28 September recorded the lowest increase since March 2021. Only 18,795 new cases and 179 deaths were recorded in a day. (with information from Reuters)